4.1 Review

Earlier testing for HIV - how do we prevent late presentation?

期刊

ANTIVIRAL THERAPY
卷 15, 期 -, 页码 17-24

出版社

INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1526

关键词

-

资金

  1. Bristol-Myers Squibb
  2. Abbott Laboratories
  3. Gilead
  4. MSD
  5. GlaxoSmithKline
  6. Pharmacia
  7. Pfizer
  8. Boehringer-Ingelheim
  9. Roche
  10. Schering-Plough
  11. Swedish Orphan
  12. Tibotec

向作者/读者索取更多资源

HIV testing policies and practices vary widely across Europe. It is clear that there are individuals who might present late for HIV diagnosis and care within all risk groups, and potentially in any healthcare setting. This article explores the need to ensure earlier identification and treatment of late-presenting patients by reviewing strategies that might be considered. Such strategies could include routine provider-initiated HIV testing of at-risk groups in settings such as sexually transmitted infection clinics, drug dependency programmes or antenatal care. Healthcare providers might also consider routine HIV testing in all healthcare facilities, in settings including emergency and primary care, where local HIV prevalence is above a threshold that should be further evaluated. They should also take advantage of rapid testing technologies and be aware of barriers to HIV testing among specific groups to provide opportunities for testing that are relevant to local communities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据